The European Medicines Agency's CHMP has issued a positive opinion recommending marketing authorization for Ascendis Pharma's once-weekly Yuviwel (navepegritide) to treat pediatric achondroplasia in children aged two and older. Backed by Phase 2b ApproaCH trial data showing improved growth velocity and skeletal alignment, a final European Commission decision is expected in Q4 2026, with an initial European launch planned for Germany in Q1 2027.
Regulatory approvals and timeline in Europe and US
- ▪A final decision by the European Commission regarding Ascendis Pharma's Marketing Authorisation Application for TransCon CNP is expected during the fourth quarter of 2026.
- ▪The European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization for once-weekly Yuviwel (navepegritide) to treat achondroplasia in children aged two and older whose epiphyses are not closed.
- ▪Yuviwel marketing authorization in the European Union requires achondroplasia diagnosis confirmation by appropriate genetic testing.
- ▪The U.S. Food and Drug Administration approved once-weekly TransCon CNP under the trade name Yuviwel in February 2026 to increase linear growth in pediatric achondroplasia patients two years and older with open epiphyses.
Orphan medicine designation
- ▪At the time of TransCon CNP's orphan designation in 2020, achondroplasia affected roughly 0.6 in 10,000 people in the European Union.
- ▪The European Medicines Agency designated TransCon CNP as an orphan medicine during its development and will review whether to maintain the designation.
Ascendis Pharma commercial plans and launch strategy
- ▪Ascendis Pharma Chief Executive Officer Jan Mikkelsen stated that TransCon CNP remains a foundational product in the company's growth disorder portfolio in support of Vision 2030 objectives.
- ▪Ascendis Pharma plans to supply Yuviwel as a powder and solvent for injection in dosage strengths of 1.3 milligrams, 2.8 milligrams, and 5.5 milligrams.
- ▪If authorized by the European Commission, Ascendis Pharma expects to conduct its first European Union launch of Yuviwel in Germany during the first quarter of 2027.
Drug composition and mechanism of action
- ▪Following subcutaneous injection, Yuviwel's linker autocleaves at physiologic pH and temperature to provide continuous exposure to active C-type natriuretic peptide over a weekly dosing interval.
- ▪Active C-type natriuretic peptide binds to natriuretic peptide receptor B to generate cyclic GMP, counteracting overactive FGFR3 signaling and promoting chondrocyte proliferation.
- ▪Yuviwel contains navepegritide, a C-type natriuretic peptide prodrug that transiently links active C-type natriuretic peptide to an inert carrier using TransCon technology.
Efficacy and safety in ApproaCH trial
- ▪In the ApproaCH trial, navepegritide improved lower-limb skeletal alignment measures at week 52, showing a 1.81-degree reduction in tibial-femoral angle and a 2.78-millimeter reduction in mechanical axis deviation compared to placebo.
- ▪In the 52-week Phase 2b ApproaCH trial of 84 pediatric participants aged 2 to 11 years, weekly navepegritide increased annualized growth velocity to 5.89 centimeters per year compared to 4.41 centimeters per year for placebo.
- ▪In the ApproaCH trial, navepegritide demonstrated a safety profile similar to placebo, with injection site reactions, fever, nasopharyngitis, and otitis media among reported adverse events.
- ▪In the ApproaCH trial, pediatric participants under five years old receiving navepegritide experienced improved physical functioning on the Achondroplasia Child Experience Measures scale.
Achondroplasia prevalence and clinical manifestations
- ▪Expressed in tissues throughout the body, the FGFR3 variant causes disproportionate short stature and skeletal dysplasia alongside serious muscular, neurological, and cardiorespiratory complications.
- ▪Skeletal complications of achondroplasia include spinal kyphosis, lordosis, spinal stenosis causing nerve compression, and progressive leg bowing from relative fibular overgrowth.
- ▪Achondroplasia is a rare genetic condition caused by a pathogenic variant in the FGFR3 gene that affects an estimated 250,000 people globally and 30,000 people in the European Union.
Story comments
Loading comments…